Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Navigating the Path to Compliance: Two Pharmas Discuss Their Challenges and Successes
Novartis CEO says he’s committed to ethics. So prove it—Editor’s Corner
Thursday, May 10, 2018
After round-the-world scandals, it certainly appears Novartis has a systemic problem. But Vas Narasimhan has a clean slate—and he needs to use it.
Rheumatology Adherence Data: Real-Time Stats on Medisafe that Pharma Should Know
Greek prosecutor ratchets up inquiries in Novartis bribery probe
Wednesday, April 4, 2018
A prosecutor in Greece who is investigating bribery allegations against Novartis is probing the financial assets of more than 30 former politicians.
Greek prime minister policing Novartis bribery investigation
Friday, February 9, 2018
Days after 10 ex-ministers in Greece were dragged into a Novartis bribery probe, three former execs believed to be key witnesses have come under fire.
Novartis manager's travel restricted amid bribery probe: report
Tuesday, February 6, 2018
One year after officials in Greece began investigating Novartis on bribery allegations, the country’s leaders are ratcheting up the probe.
FDA cites third Dr. Reddy's plant this year
Monday, May 1, 2017
FDA inspectors continue to roll through Dr. Reddy’s plants in India and continue to find issues along the way.
Request for a pause may kill FDA quality metrics proposal
Monday, April 10, 2017
The industry is asking the FDA to pause enactment of guidance that would require manufacturers to report their progress on meeting quality metrics.
FDA smacks third Alkem plant with Form 483
Tuesday, March 14, 2017
FDA inspectors began rolling through the plants of India’s Alkem Laboratories last year and have now found issues with a third Alkem facility.
India to start fresh on pharma oversight by reworking 75-year-old law
Wednesday, June 22, 2016
In a move some might call long overdue, India is poised to revamp a 75-year-old law governing the pharma business, hoping to improve clinical trial oversight and boost manufacturing quality.